This observation predicts that ATRX mutant tumour cells might be more sensitive to Pol I transcription inhibition and therefore could be used for stratification of patients with cancer such as glioblastoma and neuroendocrine and prostate cancer that harbour ATRX mutations. This evidence concerns the gene ATRX and Familial prostate cancer.